Last $103.25 USD
Change Today +0.91 / 0.89%
Volume 962.1K
SLXP On Other Exchanges
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

salix pharmaceuticals ltd (SLXP) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/24/14 - $172.98
52 Week Low
12/11/13 - $82.52
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

salix pharmaceuticals ltd (SLXP) Related Businessweek News

No Related Businessweek News Found

salix pharmaceuticals ltd (SLXP) Details

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. The company provides XIFAXAN tablets to treat overt hepatic encephalopathy, and patients with travelers’ diarrhea; APRISO too maintain remission of ulcerative colitis (UC); MOVIPREP and OSMOPREP for cleansing of the colon as a preparation for colonoscopy in adults; RELISTOR for the treatment of opioid-induced constipation (OIC) in patients with advanced illness; SOLESTA to treat fecal incontinence; and DEFLUX to treat vesicoureteral reflux. It also offers FULYZAQ for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy; GIAZO, COLAZAL, and UCERIS to treat mildly to moderately active UC; and METOZOLV ODT for the treatment of refractory gastroesophageal reflux disease (GERD) that fails to respond to conventional therapy. Its products also comprise AZASAN azathioprine tablets, which are used as adjunct to prevent rejection in renal homotransplantations and to reduce signs and symptoms of severe active rheumatoid arthritis; ANUSOL-HC and PROCTOCORT for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; and PEPCID for the short-term treatment of GERD, active duodenal ulcer, active benign gastric ulcer, erosive esophagitis due to GERD, and peptic ulcer diseases. In addition, the company provides DIURIL to treat hypertension and also as adjunctive therapy; ZEGERID for the treatment of upper gastrointestinal conditions; GLUMETZA and CYCLOSET to enhance glycemic control in adults with type 2 diabetes mellitus; and FENOGLIDE to treat lipoprotein-cholesterol, total cholesterol, triglycerides, and apolipoprotein B, as well as hypertriglyceridemia. It has strategic collaboration with RedHill Biopharma Ltd. Salix Pharmaceuticals, Ltd. was founded in 1989 and is headquartered in Raleigh, North Carolina.

555 Employees
Last Reported Date: 02/28/14
Founded in 1989

salix pharmaceuticals ltd (SLXP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $867.5K
Chief Development Officer, Chief Medical Offi...
Total Annual Compensation: $466.4K
Executive Vice President of Business Developm...
Total Annual Compensation: $437.0K
Compensation as of Fiscal Year 2013.

salix pharmaceuticals ltd (SLXP) Key Developments

Salix Pharmaceuticals Ltd. and Pharming Group NV Announce Launch of Hereditary Angioedema Drug in Us

Salix Pharmaceuticals Ltd. and Pharming Group NV announce the launch of RUCONEST 50IU/kg in the US for the treatment of acute angioedema attacks in adult and adolescent patients with hereditary angioedema, or HAE. Effectiveness in clinical studies was not established in HAE patients with laryngeal attacks. RUCONEST is available by prescription across the US through RUCONEST SOLUTIONS and comes with comprehensive patient support services. RUCONEST is manufactured by Pharming Group NV in the Netherlands. Salix has licensed exclusive rights from Pharming to commercialize RUCONEST in North America and market RUCONEST for the treatment of acute HAE attack symptoms.

Labaton Sucharow LLP Files Class Action Lawsuit on Behalf of Investors in Salix Pharmaceuticals, Ltd

Labaton Sucharow LLP filed a securities class action lawsuit on behalf of Woburn Retirement System in the U.S. District Court for the Southern District of New York. The lawsuit was filed on behalf of all persons or entities who, between November 8, 2013 and November 6, 2014, inclusive (Class Period), purchased or otherwise acquired the securities of Salix Pharmaceuticals Ltd. The complaint alleges that the defendants made false and misleading statements and concealed material information regarding deteriorating demand for Xifaxan and other Salix drugs and wholesaler inventory levels of Xifaxan and other Salix drugs, which were significantly greater and rising more rapidly than revealed to investors. The complaint also claims that Salix's reserves for outstanding inventory were understated and, because of this understatement, its reported quarterly and annual net revenue and earnings per share figures were overstated, and that Salix's disclosure controls and procedures and its internal controls over financial reporting and accounting were subject to material weaknesses.

Salix Pharmaceuticals, Ltd. Announces Executive Changes

Salix Pharmaceuticals Ltd. announced the appointment of Timothy J. Creech as acting chief financial officer of the Company, effective immediately. He succeeds Adam C. Derbyshire, who resigned as the Executive Vice President, Finance and Administration, and Chief Financial Officer. Creech, who joined the company in 2007, has most recently been serving as the company's senior vice president, finance and administrative services. Creech has over 30 years of accounting and financial experience, including approximately 10 years at KPMG LLP and over 20 years in positions of significant responsibility at publicly traded companies.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SLXP:US $103.25 USD +0.91

SLXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $55.01 USD +0.84
Almirall SA €13.60 EUR +0.09
Cubist Pharmaceuticals Inc $75.65 USD +0.69
Recordati SpA €13.94 EUR +0.12
Santen Pharmaceutical Co Ltd ¥6,630 JPY -10.00
View Industry Companies

Industry Analysis


Industry Average

Valuation SLXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.8x
Price/Book 12.5x
Price/Cash Flow 66.4x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SALIX PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at